Healthcare -
Biotechnology - NASDAQ - US
$ 1.36
-2.86 %
$ 77.1 M
Market Cap
-1.07
P/E
1. INTRINSIC VALUE
FINANCIALS
Balance Sheet
Black Diamond Therapeutics, Inc.
| Current Assets | 101 M |
| Cash & Short-Term Investments | 98.6 M |
| Receivables | 0 |
| Other Current Assets | 2.6 M |
| Non-Current Assets | 21.5 M |
| Long-Term Investments | 0 |
| PP&E | 20.4 M |
| Other Non-Current Assets | 1.07 M |
| Current Liabilities | 20.6 M |
| Accounts Payable | 4.01 M |
| Short-Term Debt | 0 |
| Other Current Liabilities | 16.6 M |
| Non-Current Liabilities | 18.8 M |
| Long-Term Debt | 18.8 M |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Black Diamond Therapeutics, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 78.8 M |
| Operating Income | -78.8 M |
| Other Expenses | -9.1 M |
| Net Income | -69.7 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Black Diamond Therapeutics, Inc.
| Net Income | -69.7 M |
| Depreciation & Amortization | 343 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 10.6 M |
| Change in Working Capital | -2.69 M |
| Others | -5.28 M |
| Free Cash Flow | -62.3 M |
Wall Street Analysts Price Targets
Black Diamond Therapeutics, Inc.
Wall Street analysts predict an average 1-year price target for BDTX of $14.3 , with forecasts ranging from
a
low of
$11 to a high of $20 .
BDTX Lowest Price Target
Wall Street Target
11 USD
708.82%
BDTX Average Price Target
Wall Street Target
14.3 USD
953.92%
BDTX Highest Price Target
Wall Street Target
20 USD
1370.59%
4. DIVIDEND
ANALYSIS
BDTX does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Black Diamond Therapeutics, Inc.
Sold
0-3 MONTHS
12 M USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
1.4 M USD 1
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences.
globenewswire.com
- 1 week ago
Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With Servier
Black Diamond Therapeutics' strategic deal with Servier makes BDTX undervalued, with a $70M upfront payment and potential $710M in milestone payments and royalties. BDTX is trading below its net cash of $2.30 per share, presenting a major buying opportunity despite past shareholder losses. Aggressive selling by Biotech Growth N.V. caused recent price volatility, but this creates a buying opportunity given BDTX's strong fundamentals.
seekingalpha.com
- 2 weeks ago
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
SURESNES, France and CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Servier, an independent global pharmaceutical group governed by a non-profit foundation, and Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced a strategic worldwide licensing agreement for BDTX-4933, a potential best-in-class targeted therapy for solid tumors. Under this global agreement, Servier will develop and commercialize BDTX-4933, a small molecule designed by Black Diamond Therapeutics to address unmet medical needs in RAF/RAS-mutant solid tumors.
globenewswire.com
- 3 weeks ago
Black Diamond Therapeutics: In Decline, But Why?
Black Diamond Therapeutics, Inc. shows promising developments in its pipeline updates, highlighting significant advancements in targeted cancer therapies. The financial overview reveals a stable cash position, supporting ongoing research and development efforts without immediate capital concerns. Strengths include a robust pipeline and innovative approach, while risks involve clinical trial uncertainties and market competition.
seekingalpha.com
- 1 month ago
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a corporate update.
globenewswire.com
- 1 month ago
Black Diamond Therapeutics: Speculative Buy With Precision Oncology Catalysts
Black Diamond Therapeutics, Inc.'s BDTX-1535 showed a promising 42% ORR in Phase 2 trials for recurrent EGFR-mutant NSCLC, which addresses treatment-resistant mutations. The MasterKey platform enables targeting entire families of oncogenic mutations, offering potential solutions for underserved cancer populations like non-classical NSCLC and glioblastoma. BDTX's $112.7 million cash reserves will support operations through Q2 2026. Restructuring efforts will prioritize high-value programs like BDTX-1535.
seekingalpha.com
- 3 months ago
Black Diamond (BDTX) Upgraded to Buy: Here's What You Should Know
Black Diamond (BDTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
zacks.com
- 4 months ago
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update.
globenewswire.com
- 5 months ago
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows:
globenewswire.com
- 5 months ago
Black Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 Data
Preliminary results from phase 2 study using BDTX-1535 for the treatment of 1st-line EGFRm NSCLC patients, expected in Q1 of 2025. Updated cohort results from the phase 2 study using BDTX-1535 for the treatment of 2nd-line/3rd-line EGFRm NSCLC patients, expected in Q1 of 2025. Company to meet with the FDA in Q1 of 2025 and provide update on possible registration study to move BDTX-1535 program forward in the clinic.
seekingalpha.com
- 6 months ago
Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway
Company advancing BDTX-1535 in EGFRm NSCLC towards key inflection points in Q1 2025 Will deprioritize BDTX-4933 and seek potential partners Anticipated cost savings expected to extend cash runway into Q2 2026 CAMBRIDGE, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, announced today a corporate restructuring to focus resources on advancing lead program BDTX-1535 into pivotal development, and to extend the Company's expected cash runway into Q2 2026.
globenewswire.com
- 6 months ago
Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations
BDTX-1535 dose of 200 mg daily selected for pivotal development; favorable tolerability profile and no new safety signals observed
globenewswire.com
- 6 months ago
8. Profile
Summary
Black Diamond Therapeutics, Inc. BDTX
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 77.1 M
Dividend Yield
0.00%
Description
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Contact
One Main Street, Cambridge, MA, 02142
https://www.blackdiamondtherapeutics.com
IPO
Date
Jan. 31, 2020
Employees
24
Officers
Ms. Melanie Morrison
Chief Development Officer
Dr. Sergey Yurasov M.D., Ph.D.
Chief Medical Officer
Ms. Erika Jones
Principal Financial Officer, Principal Accounting Officer, SVice President of Finance & Corporate Controller
Mr. Brent Hatzis-Schoch Esq., J.D.
Chief Operating Officer & General Counsel
Dr. Elizabeth Buck Ph.D.
Co-Founder & Chief Scientific Officer
Ms. Elizabeth L. Montgomery
Chief People Officer
Dr. Mark A. Velleca M.D., Ph.D.
Chief Executive Officer, President & Chairman
Dr. David M. Epstein Ph.D.
Co-Founder & Director